Pliant Therapeutics (PLRX) Common Equity (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Common Equity of $165.2 million for Q1 2026, down 35.77% year-over-year from $257.2 million in Q1 2025, and down 8.85% quarter-over-quarter from $181.2 million in Q4 2025.
Pliant Therapeutics (PLRX) Common Equity (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Common Equity for 8 consecutive years, with $165.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 35.77% year-over-year to $165.2 million; the TTM figure through Mar 2026 stood at $165.2 million (down 35.77% YoY), while the FY2025 annual figure was $181.2 million, down 40.41% from the prior year.
- Common Equity eased to $165.2 million in Q1 2026 per PLRX's latest filing, from $181.2 million in the prior quarter.
- Across five years, Common Equity topped out at $561.9 million in Q1 2023 and bottomed at $147.8 million in Q2 2022.
- Historically, Common Equity has averaged $326.3 million across 5 years, with a median of $313.3 million in 2022.
- Annual changes were most pronounced in 2023 — Common Equity soared 260.7% — and 2025, when it plunged 43.95%.
- Pliant Therapeutics' Common Equity stood at $313.3 million in 2022, then soared by 51.14% to $473.6 million in 2023, then slumped by 35.79% to $304.1 million in 2024, then plunged by 40.41% to $181.2 million in 2025, then dropped by 8.85% to $165.2 million in 2026.
- Business Quant data shows PLRX's Common Equity at $165.2 million in Q1 2026, $181.2 million in Q4 2025, and $200.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 146.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.93 Mn |
| Mar 31, 2026 | 165.17 Mn |
| Dec 31, 2025 | 181.21 Mn |
| Sep 30, 2025 | 200.31 Mn |
| Jun 30, 2025 | 220.08 Mn |
| Mar 31, 2025 | 257.16 Mn |
| Dec 31, 2024 | 304.08 Mn |
| Sep 30, 2024 | 345.82 Mn |
| Jun 30, 2024 | 392.68 Mn |
| Mar 31, 2024 | 437.33 Mn |
| Dec 31, 2023 | 473.58 Mn |
| Sep 30, 2023 | 503.05 Mn |
| Jun 30, 2023 | 533.07 Mn |
| Mar 31, 2023 | 561.92 Mn |
| Dec 31, 2022 | 313.34 Mn |
| Sep 30, 2022 | 336.99 Mn |
| Jun 30, 2022 | 147.79 Mn |
| Mar 31, 2022 | 173.79 Mn |
| Dec 31, 2021 | 199.06 Mn |
| Sep 30, 2021 | 220.44 Mn |